List of Excipients in Branded Drug DILTIAZEM HCL CD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	DILTIAZEM HCL CD	diltiazem hydrochloride	68682-521	CELLULOSE, MICROCRYSTALLINE
Oceanside Pharmaceuticals	DILTIAZEM HCL CD	diltiazem hydrochloride	68682-521	ETHYL ACRYLATE
Oceanside Pharmaceuticals	DILTIAZEM HCL CD	diltiazem hydrochloride	68682-521	FD&C BLUE NO. 1

Diltiazem HCl CD Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Diltiazem hydrochloride extended-release capsules are an off-patent, small-molecule opportunity centered on multiparticulate controlled release, excipient reproducibility, and differentiated dosage forms. The strongest commercial strategy is a robust generic or 505(b)(2) product that matches the reference product’s release profile, capsule-opening performance, food effect, and dose-escalation range while improving manufacturing efficiency or patient convenience.

What is Diltiazem HCl CD?

Diltiazem HCl CD is an extended-release oral capsule containing diltiazem hydrochloride. The “CD” designation generally refers to a controlled-delivery formulation rather than a new active pharmaceutical ingredient.

Cardizem CD, the reference product, is indicated for hypertension and chronic stable angina. The product is supplied in multiple strengths, including 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg capsules, depending on market authorization and product presentation. The dosage form uses coated multiparticulate units designed to release diltiazem over an extended period.[1]

Diltiazem is a calcium-channel blocker. The commercial formulation challenge is not the chemical novelty of the API. It is the delivery system. An immediate-release diltiazem tablet and an extended-release multiparticulate capsule can have materially different exposure profiles, dosing frequency, food effects, and tolerability.

What excipients are used in Diltiazem HCl CD capsules?

The reference formulation uses a multiparticulate platform with inert cores, drug layering, polymeric coating, and a hard gelatin capsule shell. Public labeling identifies excipient classes that include sugar spheres, hypromellose, ethylcellulose, povidone, talc, and capsule-shell components such as gelatin, titanium dioxide, and permitted colorants.[1]

Exact excipient quantities and coating-process parameters are generally proprietary. A generic manufacturer does not need to duplicate every excipient by name or grade. It must demonstrate pharmaceutical equivalence and bioequivalence and control critical quality attributes.

Formulation component	Likely function	Commercial relevance
Sugar spheres or other inert cores	Multiparticulate substrate	Controls drug-layer uniformity and particle-size distribution
Diltiazem HCl	Active ingredient	High aqueous solubility makes release control more dependent on coating and matrix design
Povidone or comparable binder	Drug-layer adhesion	Affects loading uniformity, friability, and coating integrity
Hypromellose	Binder, film former, or release-modifying polymer	Influences coating continuity and aqueous hydration
Ethylcellulose	Water-insoluble release-control polymer	Main barrier to rapid drug release
Talc or similar anti-tacking agent	Reduces agglomeration during coating	Affects process yield and coating uniformity
Gelatin capsule shell	Primary dosage-form enclosure	Affects moisture exposure, appearance, and capsule-opening performance
Titanium dioxide and colorants	Opacity and product identification	Relevant to patient acceptance and regulatory comparability

An excipient substitution is commercially viable when the substitute performs the same functional role and the finished product maintains equivalent dissolution and pharmacokinetic behavior. The critical issue is the total formulation and process interaction, not the individual excipient list.

How should an excipient strategy be designed for Diltiazem HCl CD?

The preferred platform is a coated-pellet or coated-bead system. Multiparticulates distribute the dose across many individual units and can reduce the clinical effect of localized defects compared with a single monolithic matrix tablet.

Release-control polymer selection

Ethylcellulose is a logical primary release-control polymer because it forms a water-insoluble membrane and can be adjusted through coating weight gain, plasticizer selection, pore-former content, and film thickness. Commercial alternatives include aqueous ethylcellulose dispersions, organic-solvent coatings, methacrylate copolymers, and hydrophilic matrix systems.

A practical development sequence is:

1. Establish a pellet-size and drug-loading range.
2. Screen polymer type and coating weight.
3. Optimize plasticizer and anti-tacking levels.
4. Add pore-forming material only where needed.
5. Match dissolution across acidic and buffer stages.
6. Confirm stability under high-temperature and high-humidity conditions.
7. Evaluate capsule opening and sprinkling, if that claim is pursued.

A lower coating weight can improve manufacturing cost and throughput but may increase sensitivity to coating defects. A higher coating weight can improve robustness while increasing process time, solvent or water demand, and capsule fill mass.

Plasticizers and anti-tacking agents

Plasticizers such as triethyl citrate or polyethylene glycol can improve film flexibility and reduce cracking. Excess plasticizer can increase permeability and accelerate release. Talc or colloidal silicon dioxide can reduce pellet agglomeration, but excessive levels may interfere with coating uniformity or create downstream segregation.

Capsule shell strategy

Hard gelatin is the conventional shell material. Hypromellose capsules may offer a commercial alternative where moisture control, vegetarian positioning, or shell supply diversification is important. The change requires evaluation of:

• Moisture transmission.
• Mechanical integrity.
• Capsule dissolution.
• Pellet migration.
• Stability.
• Filling-machine performance.
• Visual and labeling comparability.

A hypromellose shell is not automatically a market advantage. The benefit is strongest where the target market values non-gelatin dosage forms or where gelatin supply and storage conditions create operational risk.

Excipient sourcing and dual qualification

The formulation should avoid dependence on a single supplier for the release-controlling polymer, capsule shell, or inert pellets. Dual sourcing must be performed by functional equivalence, not merely by compendial compliance.

For each critical excipient, the sponsor should control:

• Viscosity or polymer substitution grade.
• Particle-size distribution.
• Moisture content.
• Bulk and tapped density.
• Residual solvents, where applicable.
• Microbial quality.
• Peroxide and aldehyde levels for sensitive excipients.
• Coating dispersion stability.
• Lot-to-lot dissolution impact.

A change in ethylcellulose grade, sugar-sphere size, or hypromellose viscosity can shift the release profile even when the change remains within a monograph.

What formulation patents protect Diltiazem HCl CD?

The original commercial value of Cardizem CD was associated with controlled-release delivery technology, dose strengths, manufacturing processes, and clinical use rather than a new diltiazem molecule. The active ingredient and legacy extended-release capsule technology are generally treated as off-patent for ordinary generic-development purposes.

A sponsor should still screen:

• U.S. patents listed for the reference product in the Orange Book.
• Continuations and divisionals covering release profiles or manufacturing.
• Patent families covering multiparticulate delivery.
• Method-of-use claims for hypertension or angina.
• Foreign patents relevant to export markets.
• Product-specific trade dress and capsule appearance rights.

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with approved reference products.[2] For a legacy diltiazem ER capsule, the commercial barrier is normally abbreviated approval, product development, and manufacturing execution rather than an active composition-of-matter patent.

When does Diltiazem HCl CD lose exclusivity?

Diltiazem HCl CD has no meaningful remaining composition-of-matter exclusivity in the United States. The original active ingredient is long off-patent, and extended-release diltiazem capsules have been marketed by multiple generic manufacturers.

Exclusivity category	Diltiazem HCl CD position
New chemical entity exclusivity	Expired
Composition-of-matter patent	Expired or commercially irrelevant
Reference-product exclusivity	No current barrier expected for a legacy product
Pediatric exclusivity	Not a current commercial barrier
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Generic approval pathway	Generally ANDA, subject to reference-product and listing analysis

FDA approval of a generic product depends on pharmaceutical equivalence, bioequivalence, quality, labeling, and manufacturing compliance. The applicant must identify the correct reference listed drug and comply with any applicable patent certifications.[3]

What is the Orange Book status of Diltiazem HCl CD?

The Orange Book should be reviewed by NDA, strength, dosage form, and reference-listed-drug designation. “Diltiazem HCl CD” is not sufficient by itself to establish the relevant regulatory record because several diltiazem extended-release products and dosage forms have been approved.

The commercial assessment should verify:

• NDA number for the reference product.
• Reference-listed-drug status by strength.
• Approved generic strengths.
• Therapeutic-equivalence codes.
• Listed patents and pediatric exclusivity.
• Withdrawal status of individual strengths.
• Any difference between once-daily capsules and other extended-release products.

A generic capsule cannot assume substitutability merely because it contains the same active ingredient and nominal strength. Release characteristics and dosage-form design determine the relevant regulatory pathway.

How many patents cover Diltiazem HCl CD?

No active foundational patent should be assumed to block development of a conventional diltiazem HCl extended-release capsule. The relevant patent count is product-specific and must be determined from current Orange Book records and global patent databases.

Potentially relevant patent categories include:

1. Drug-layered pellets.
2. Polymer-coated multiparticulates.
3. Specific dissolution profiles.
4. Capsule formulations with sprinkle administration.
5. Food-effect reduction.
6. Manufacturing processes.
7. Combination products.
8. New therapeutic uses.

The practical patent risk is low for a standard generic but can increase for a differentiated product that claims a new release profile, pediatric administration method, or improved pharmacokinetic characteristic.

What Paragraph IV challenges and litigation affect Diltiazem HCl CD?

A Paragraph IV certification is relevant only when an applicant identifies an unexpired listed patent and asserts that the patent is invalid, unenforceable, or not infringed. For a legacy diltiazem extended-release capsule, the expected development posture is generally a Paragraph III or “no relevant patent listed” strategy, subject to the current Orange Book record.[2]

No biosimilar pathway applies because diltiazem is a chemically synthesized small molecule. Competition arises through ANDAs, not 351(k) applications.

The litigation risk profile is therefore different from that of newer branded medicines:

Risk area	Assessment
Composition-of-matter litigation	Low
Biosimilar litigation	Not applicable
Formulation patent litigation	Product-specific and potentially material
Manufacturing-process disputes	Possible for differentiated platforms
Trademark or trade-dress disputes	Manageable through distinct branding
Regulatory litigation	Possible if approval or therapeutic-equivalence decisions are challenged

Historical settlements, if any, should be assessed from individual court dockets and FDA records rather than inferred from the presence of generic products.

What generic launch opportunities exist for Diltiazem HCl CD?

The basic generic opportunity is mature, but commercial openings remain in supply reliability, low-cost manufacturing, dose breadth, and patient administration.

Standard ANDA capsule

The lowest-risk opportunity is a conventional extended-release capsule matching the reference product’s strengths and release profile. Success depends on:

• Bioequivalence at relevant strengths.
• Robust multiparticulate coating.
• Reliable capsule filling.
• Competitive cost of goods.
• Multi-source excipient procurement.
• Complete commercial-scale process validation.

Sprinkle formulation

A capsule that can be opened and sprinkled on soft food may address patients who have difficulty swallowing capsules. This claim requires specific administration studies and labeling support. The pellets must resist crushing and maintain the intended release profile after capsule opening.

This is a high-value differentiation opportunity because it depends on the dosage form, not only on the API. It also creates additional risks involving food compatibility, pellet retention, and dose recovery.

Lower-cost aqueous coating process

An aqueous ethylcellulose process can reduce reliance on organic solvents and simplify environmental controls. The development cost may be higher initially because drying, curing, and film-coalescence conditions must be tightly controlled.

The commercial benefit can include:

• Lower solvent-handling burden.
• Improved worker-safety profile.
• Easier scale-up.
• Lower environmental compliance cost.
• Better alignment with modern manufacturing expectations.

Strength and pack-size optimization

The product can be positioned around the most commercially attractive strengths rather than launching every possible strength. Hypertension and angina markets may support different demand patterns. Institutional buyers often prioritize continuity of supply and broad strength coverage, while retail buyers place greater emphasis on reimbursement and acquisition cost.

International licensing

Licensing opportunities are strongest where a partner has:

• An established ANDA or national generic approval.
• Existing capsule-filling and pellet-coating capacity.
• Government-tender access.
• Local pharmacovigilance infrastructure.
• Registration capability in markets recognizing U.S. or European data.

The licensor can provide formulation know-how, analytical methods, and scale-up support. The licensee can provide regional registration and commercialization. No specific licensing transaction should be presumed without a documented agreement.

How strong is the patent estate for Diltiazem HCl CD?

The patent estate is weak for a standard generic and potentially moderate for a differentiated delivery system. The active ingredient provides no meaningful exclusivity. Competitive protection must come from manufacturing know-how, regulatory execution, supply-chain control, or new claims supported by clinical and pharmacokinetic data.

Asset	Relative protection
Diltiazem HCl API	Very low
Conventional ER capsule	Low
Coated-pellet process parameters	Moderate as trade secret
Specific dissolution profile	Potentially moderate
Sprinkle administration	Potentially moderate
Novel capsule shell or packaging	Low to moderate
Supplier qualification and scale-up knowledge	High operational value
Approved product and market access	High near-term commercial value

The most defensible assets may not be patent claims. They may be validated coating parameters, supplier relationships, analytical discrimination methods, and a clean regulatory history.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barrier is uniformity. Each pellet must receive a consistent drug layer and polymer coating. Small shifts in spray rate, atomization, inlet temperature, bed temperature, solids content, or curing can alter dissolution.

Critical process parameters include:

• Inert-core size distribution.
• Drug-layer weight gain.
• Coating weight gain.
• Spray rate.
• Atomization pressure.
• Product temperature.
• Polymer dispersion solids.
• Plasticizer ratio.
• Curing time and temperature.
• Capsule fill-weight control.

Analytical methods must discriminate between acceptable and unacceptable release profiles. A method that is insufficiently sensitive to coating defects can allow production lots to pass development testing while failing comparative dissolution or stability studies.

Packaging is also relevant. Moisture uptake can affect capsule shell integrity and polymer permeability. High-barrier blister packaging or bottles with desiccant may improve stability but increase cost.

How does Diltiazem HCl CD compare with other diltiazem products?

Product type	Dosing pattern	Formulation challenge	Commercial position
Immediate-release tablet	Multiple daily doses	Rapid dissolution and tolerability	Mature, low differentiation
Extended-release tablet	Once or twice daily	Matrix robustness and dose dumping control	Competes on price and supply
Extended-release capsule	Usually once daily	Pellet coating and capsule performance	Strongest opportunity for formulation differentiation
Sprinkle capsule	Once daily	Administration after capsule opening	Patient-convenience niche
Injectable diltiazem	Acute-care use	Sterility and parenteral stability	Separate regulatory and manufacturing platform

A capsule-based product can compete against extended-release tablets but should not assume automatic interchangeability across all diltiazem ER products. The regulatory reference product and therapeutic-equivalence code determine substitution status.

What is the FDA regulatory pathway for Diltiazem HCl CD?

The standard pathway is an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish sameness of active ingredient, dosage form, strength, route of administration, labeling subject to permitted differences, and bioequivalence.[3]

A 505(b)(2) application may be relevant where the sponsor proposes a clinically meaningful change that cannot be supported entirely through the ANDA framework, such as:

• A new sprinkle indication.
• A different dosage form.
• A novel release profile.
• A new patient population.
• A clinically supported food-effect improvement.

The 505(b)(2) route can support differentiation but increases clinical, regulatory, and commercial costs.

Key Takeaways

• Diltiazem HCl CD is primarily a multiparticulate controlled-release formulation opportunity.
• The reference-product platform relies on drug-layered units and polymeric release control.
• Ethylcellulose, hypromellose, binders, anti-tacking agents, and capsule-shell materials are the main excipient strategy variables.
• Diltiazem has no meaningful biosimilar risk because it is a small molecule.
• Standard generic entry is generally an ANDA opportunity, subject to current Orange Book review.
• The foundational patent barrier is expected to be low, but product-specific formulation and process claims require screening.
• The strongest commercial niches are sprinkle administration, supply reliability, aqueous coating, selected strengths, and international licensing.
• Manufacturing know-how may provide greater practical protection than patents.
• The key technical risks are coating uniformity, dissolution discrimination, food effects, moisture sensitivity, and capsule-opening performance.

FAQs About Diltiazem HCl CD Excipient and Market Strategy

Can ethylcellulose be replaced in a generic Diltiazem HCl CD formulation?

Yes. A substitute release-control polymer may be used if the finished product meets regulatory requirements for pharmaceutical equivalence, dissolution, bioequivalence, stability, and labeling.

Is Diltiazem HCl CD suitable for a 505(b)(2) product?

It can be, particularly for a novel sprinkle product, new delivery system, or clinically supported pharmacokinetic improvement. A conventional equivalent capsule is generally better suited to the ANDA pathway.

Does Diltiazem HCl CD have biosimilar competition?

No. Diltiazem is a chemically synthesized small molecule. Competition is expected through generic ANDAs rather than biosimilar applications.

Can Diltiazem HCl CD capsules be opened and sprinkled on food?

Only where the approved labeling supports that method. A sponsor pursuing the claim must demonstrate that opening the capsule does not compromise dose uniformity, pellet integrity, release behavior, or bioequivalence.

Which excipient creates the greatest formulation risk?

The release-control coating system presents the greatest risk. Polymer grade, coating weight, plasticizer level, curing, and pellet-size distribution can each materially change the dissolution profile.

References

1. Bausch Health US, LLC. (n.d.). Cardizem CD: Diltiazem hydrochloride extended-release capsules prescribing information. DailyMed, U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2024). Generic drug facts and ANDA requirements. https://www.fda.gov/drugs/generic-drugs/abbreviated-new-drug-application-anda-generics

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: United States Pharmacopeial Convention.